Induction	O
of	O
the	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
during	O
T-cell	B-cell_type
activation	O
by	O
cognate	O
antigen	O
.	O

Oct-2	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
that	O
binds	O
specifically	O
to	O
octamer	B-DNA
DNA	I-DNA
motifs	I-DNA
in	O
the	O
promoters	B-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
.	O

All	O
tumor	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
and	O
a	O
few	O
from	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
express	O
Oct-2	B-protein
.	O

To	O
address	O
the	O
role	O
of	O
Oct-2	B-protein
in	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
nontransformed	B-cell_line
human	I-cell_line
and	I-cell_line
mouse	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Oct-2	B-protein
was	O
found	O
in	O
CD4+	B-cell_line
and	I-cell_line
CD8+	I-cell_line
T	I-cell_line
cells	I-cell_line
prepared	O
from	O
human	O
peripheral	O
blood	O
and	O
in	O
mouse	B-cell_type
lymph	I-cell_type
node	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
a	O
T-cell	B-cell_line
clone	I-cell_line
specific	O
for	O
pigeon	B-protein
cytochrome	I-protein
c	I-protein
in	O
the	O
context	O
of	O
I-Ek	B-protein
,	O
Oct-2	B-protein
was	O
induced	O
by	O
antigen	O
stimulation	O
,	O
with	O
the	O
increase	O
in	O
Oct-2	B-protein
protein	I-protein
seen	O
first	O
at	O
3	O
h	O
after	O
activation	O
and	O
continuing	O
for	O
at	O
least	O
24	O
h	O
.	O

Oct-2	B-RNA
mRNA	I-RNA
induction	O
during	O
antigen-driven	O
T-cell	B-cell_type
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

These	O
results	O
suggest	O
that	O
Oct-2	B-protein
participates	O
in	O
transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
activation.	O
The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	B-protein
induction	O
suggests	O
that	O
Oct-2	B-protein
mediates	O
the	O
changes	O
in	O
gene	O
expression	O
which	O
occur	O
many	O
hours	O
or	O
days	O
following	O
antigen	O
stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

MoLEcurar	NULL
anp	NULL
CELLULAR	NULL
BroLOoGY	NULL
,	NULL
July	NULL
1992	NULL
,	NULL
p.	NULL
3149-3154	NULL
0270-7306/92/073149-06	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1992	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

12	NULL
,	NULL
No	NULL
.	NULL

7	NULL
Induction	NULL
of	NULL
the	NULL
POU	NULL
Domain	NULL
Transcription	NULL
Factor	NULL
Oct-2	NULL
during	NULL
T-Cell	NULL
Activation	NULL
by	NULL
Cognate	NULL
Antigen	NULL
SANG-MO	NULL
KANG	NULL
,	NULL
``	NULL
WAYNE	NULL
TSANG	NULL
,	NULL
``	NULL
SHARON	NULL
DOLL	NULL
,	NULL
``	NULL
PEGGY	NULL
SCHERLE	NULL
,	NULL
*	NULL
HON-SUM	NULL
KO	NULL
,	NULL
``	NULL
ANNIE-CHEN	NULL
TRAN	NULL
,	NULL
MICHAEL	NULL
J.	NULL
LENARDO	NULL
,	NULL
'	NULL
anp	NULL
LOUIS	NULL
M.	NULL
STAUDT®*	NULL
Laboratory	NULL
of	NULL
Immunology	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
``	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
``	NULL
and	NULL
Metabolism	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
``	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
Received	NULL
23	NULL
December	NULL
1991/Accepted	NULL
23	NULL
April	NULL
1992	NULL
Oct-2	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
binds	NULL
specifically	NULL
to	NULL
octamer	NULL
DNA	NULL
motifs	NULL
in	NULL
the	NULL
promoters	NULL
of	NULL
immunoglobulin	NULL
and	NULL
interleukin-2	NULL
genes	NULL
.	NULL

All	NULL
tumor	NULL
cell	NULL
lines	NULL
from	NULL
the	NULL
B-cell	NULL
lineage	NULL
and	NULL
a	NULL
few	NULL
from	NULL
the	NULL
T-cell	NULL
lineage	NULL
express	NULL
Oct-2	NULL
.	NULL

To	NULL
address	NULL
the	NULL
role	NULL
of	NULL
Oct-2	NULL
in	NULL
the	NULL
T-cell	NULL
lineage	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
expression	NULL
of	NULL
Oct-2	NULL
mRNA	NULL
and	NULL
protein	NULL
in	NULL
nontransformed	NULL
human	NULL
and	NULL
mouse	NULL
T	NULL
cells	NULL
.	NULL

Oct-2	NULL
was	NULL
found	NULL
in	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
prepared	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
and	NULL
in	NULL
mouse	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
a	NULL
T-cell	NULL
clone	NULL
specific	NULL
for	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
in	NULL
the	NULL
context	NULL
of	NULL
I-E*	NULL
,	NULL
Oct-2	NULL
was	NULL
induced	NULL
by	NULL
antigen	NULL
stimulation	NULL
,	NULL
with	NULL
the	NULL
increase	NULL
in	NULL
Oct-2	NULL
protein	NULL
seen	NULL
first	NULL
at	NULL
3	NULL
h	NULL
after	NULL
activation	NULL
and	NULL
continuing	NULL
for	NULL
at	NULL
least	NULL
24	NULL
h.	NULL
Oct-2	NULL
mRNA	NULL
induction	NULL
during	NULL
antigen-driven	NULL
T-cell	NULL
activation	NULL
was	NULL
blocked	NULL
by	NULL
cyclosporin	NULL
A	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
Oct-2	NULL
participates	NULL
in	NULL
transcriptional	NULL
regulation	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
relatively	NULL
delayed	NULL
kinetics	NULL
of	NULL
Oct-2	NULL
induction	NULL
suggests	NULL
that	NULL
Oct-2	NULL
mediates	NULL
the	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
which	NULL
occur	NULL
many	NULL
hours	NULL
or	NULL
days	NULL
following	NULL
antigen	NULL
stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
octamer	NULL
DNA	NULL
motif	NULL
(	NULL
ATTTGCAT	NULL
or	NULL
close	NULL
variants	NULL
)	NULL
is	NULL
emerging	NULL
as	NULL
an	NULL
important	NULL
transcriptional	NULL
regulatory	NULL
motif	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Within	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
,	NULL
an	NULL
octamer	NULL
motif	NULL
is	NULL
present	NULL
in	NULL
a	NULL
30-bp	NULL
region	NULL
,	NULL
termed	NULL
NF-IL-2A	NULL
,	NULL
that	NULL
is	NULL
critical	NULL
for	NULL
promoter	NULL
activity	NULL
during	NULL
activation	NULL
of	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
(	NULL
6	NULL
,	NULL
13	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
generates	NULL
a	NULL
DNase-hypersensitive	NULL
site	NULL
in	NULL
the	NULL
NF-IL-2A	NULL
region	NULL
,	NULL
suggesting	NULL
that	NULL
transcription	NULL
factors	NULL
bind	NULL
to	NULL
this	NULL
sequence	NULL
in	NULL
an	NULL
inducible	NULL
fashion	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
NF-IL-2A	NULL
region	NULL
,	NULL
when	NULL
multimerized	NULL
,	NULL
functions	NULL
as	NULL
an	NULL
inducible	NULL
transcriptional	NULL
enhancer	NULL
that	NULL
responds	NULL
to	NULL
signals	NULL
delivered	NULL
by	NULL
cross-linking	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
,	NULL
and	NULL
this	NULL
enhancer	NULL
activity	NULL
depends	NULL
on	NULL
the	NULL
octamer	NULL
motif	NULL
(	NULL
2	NULL
,	NULL
4	NULL
,	NULL
15	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
immunosuppressive	NULL
agents	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK506	NULL
inhibit	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
host	NULL
of	NULL
genes	NULL
which	NULL
are	NULL
normally	NULL
induced	NULL
during	NULL
T-cell	NULL
activation	NULL
,	NULL
and	NULL
both	NULL
agents	NULL
block	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
NF-IL-2A	NULL
sequence	NULL
(	NULL
2	NULL
,	NULL
4	NULL
,	NULL
15	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Transcription	NULL
factors	NULL
which	NULL
bind	NULL
specifically	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
belong	NULL
to	NULL
the	NULL
POU	NULL
domain	NULL
multigene	NULL
family	NULL
(	NULL
12	NULL
)	NULL
.	NULL

One	NULL
member	NULL
of	NULL
this	NULL
family	NULL
,	NULL
Oct-1	NULL
,	NULL
is	NULL
expressed	NULL
in	NULL
most	NULL
cell	NULL
types	NULL
and	NULL
is	NULL
the	NULL
only	NULL
octamer-binding	NULL
protein	NULL
which	NULL
is	NULL
detectable	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
13	NULL
,	NULL
14	NULL
,	NULL
23	NULL
,	NULL
25	NULL
,	NULL
31	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Oct-1	NULL
levels	NULL
do	NULL
not	NULL
change	NULL
during	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
23	NULL
,	NULL
31	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
an	NULL
inducible	NULL
protein	NULL
interacts	NULL
with	NULL
Oct-1	NULL
and	NULL
accounts	NULL
for	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
NF-IL-2A	NULL
sequence	NULL
in	NULL
this	NULL
T-cell	NULL
tumor	NULL
line	NULL
(	NULL
13	NULL
,	NULL
30	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Another	NULL
octamer-specific	NULL
POU	NULL
domain	NULL
protein	NULL
,	NULL
Oct-2	NULL
,	NULL
is	NULL
expressed	NULL
predominantly	NULL
,	NULL
but	NULL
not	NULL
exclusively	NULL
,	NULL
in	NULL
the	NULL
B-cell	NULL
lineage	NULL
,	NULL
where	NULL
it	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
immunoglobulin	NULL
(	NULL
Ig	NULL
)	NULL
genes	NULL
(	NULL
26	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Oct-2	NULL
is	NULL
also	NULL
expressed	NULL
in	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
T-cell	NULL
tumor	NULL
lines	NULL
(	NULL
5	NULL
,	NULL
22	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
ELA	NULL
T-lymphoma	NULL
cell	NULL
line	NULL
expresses	NULL
high	NULL
levels	NULL
of	NULL
Oct-2	NULL
,	NULL
whereas	NULL
Jurkat	NULL
cells	NULL
do	NULL
not	NULL
express	NULL
detectable	NULL
Oct-2	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
an	NULL
Oct-2	NULL
expression	NULL
construct	NULL
cooperates	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
to	NULL
induce	NULL
IL-2	NULL
gene	NULL
expression	NULL
and	NULL
substitutes	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3149	NULL
for	NULL
the	NULL
phytohemagglutinin	NULL
signal	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
raise	NULL
the	NULL
interesting	NULL
possibility	NULL
that	NULL
Oct-2	NULL
has	NULL
a	NULL
role	NULL
in	NULL
gene	NULL
expression	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
expression	NULL
of	NULL
Oct-2	NULL
in	NULL
nontransformed	NULL
T	NULL
cells	NULL
and	NULL
demonstrate	NULL
here	NULL
that	NULL
Oct-2	NULL
is	NULL
induced	NULL
in	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
a	NULL
cognate	NULL
antigen	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

A.E7	NULL
is	NULL
a	NULL
nontransformed	NULL
Tpl	NULL
T-cell	NULL
clone	NULL
derived	NULL
from	NULL
a	NULL
B10.A	NULL
mouse	NULL
immunized	NULL
with	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
(	NULL
11	NULL
)	NULL
.	NULL

A.E7	NULL
cells	NULL
are	NULL
responsive	NULL
to	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
,	NULL
cyanogen	NULL
bromide	NULL
fragment	NULL
81-104	NULL
,	NULL
in	NULL
the	NULL
context	NULL
of	NULL
I-E*	NULL
.	NULL

A.E7	NULL
produces	NULL
IL-2	NULL
,	NULL
gamma	NULL
interferon	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
lymphotoxin	NULL
,	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
and	NULL
IL-3	NULL
upon	NULL
antigenic	NULL
stimulation	NULL
and	NULL
was	NULL
maintained	NULL
essentially	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
2	NULL
days	NULL
in	NULL
24-well	NULL
tissue	NULL
culture	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

at	NULL
a	NULL
concentration	NULL
of	NULL
10°	NULL
A.E7	NULL
cells	NULL
per	NULL
well	NULL
and	NULL
5	NULL
x	NULL
10°	NULL
B10.A	NULL
irradiated	NULL
(	NULL
3,000	NULL
rads	NULL
)	NULL
spleen	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
A.E7	NULL
medium	NULL
(	NULL
EHAA	NULL
medium	NULL
[	NULL
Biofluids	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
]	NULL

supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
[	NULL
Biofluids	NULL
]	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
mg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
2-mercaptoethanol	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
expanded	NULL
into	NULL
200-cm	NULL
>	NULL
flasks	NULL
(	NULL
Nunc	NULL
,	NULL
Roskilde	NULL
,	NULL
Denmark	NULL
)	NULL
in	NULL
A.E7	NULL
medium	NULL
supplemented	NULL
with	NULL
1	NULL
%	NULL
conditioned	NULL
supernatant	NULL
from	NULL
the	NULL
MLA-144	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
provides	NULL
approximately	NULL
15	NULL
U	NULL
of	NULL
IL-2	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
allowed	NULL
to	NULL
rest	NULL
for	NULL
14	NULL
to	NULL
21	NULL
days	NULL
before	NULL
use	NULL
.	NULL

DCEK	NULL
is	NULL
a	NULL
transfected	NULL
fibroblast	NULL
line	NULL
which	NULL
expresses	NULL
I-E	NULL
``	NULL
and	NULL
can	NULL
present	NULL
antigen	NULL
to	NULL
A.E7	NULL
cells	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Ron	NULL
Germain	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

DCEK	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
(	NULL
Biofluids	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Biofluids	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
mg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
2-mercaptoethanol	NULL
.	NULL

Human	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Ivan	NULL
Horak	NULL
,	NULL
Metabolism	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Be	NULL
3150	NULL
KANG	NULL
ET	NULL
AL	NULL
.	NULL

thesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

were	NULL
prepared	NULL
from	NULL
peripheral	NULL
blood	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Mouse	NULL
T	NULL
cells	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Toshio	NULL
Tanaka	NULL
,	NULL
Laboratory	NULL
of	NULL
Immunology	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

were	NULL
prepared	NULL
from	NULL
mesenteric	NULL
lymph	NULL
nodes	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Both	NULL
cell	NULL
populations	NULL
consisted	NULL
of	NULL
>	NULL
99	NULL
%	NULL
T	NULL
cells	NULL
as	NULL
determined	NULL
by	NULL
staining	NULL
with	NULL
anti-CD4	NULL
or	NULL
anti-CD8	NULL
antibodies	NULL
(	NULL
human	NULL
T	NULL
cells	NULL
)	NULL
or	NULL
a	NULL
mixture	NULL
of	NULL
anti-Thy1.2	NULL
,	NULL
anti-CD3	NULL
,	NULL
anti-CD4	NULL
,	NULL
and	NULL
anti-CD8	NULL
antibodies	NULL
(	NULL
mouse	NULL
T	NULL
cells	NULL
)	NULL
followed	NULL
by	NULL
flow	NULL
cytom-etry	NULL
on	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
&	NULL
Co.	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Cell	NULL
stimulation	NULL
.	NULL

To	NULL
selectively	NULL
assay	NULL
changes	NULL
in	NULL
Oct-2	NULL
expression	NULL
in	NULL
A.E7	NULL
T	NULL
cells	NULL
from	NULL
cultures	NULL
containing	NULL
DCEK	NULL
antigen-producing	NULL
cells	NULL
(	NULL
APC	NULL
's	NULL
)	NULL
,	NULL
a	NULL
method	NULL
of	NULL
removing	NULL
APCs	NULL
was	NULL
developed	NULL
(	NULL
13a	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
DCEK	NULL
cells	NULL
were	NULL
loaded	NULL
with	NULL
magnetic	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Great	NULL
Neck	NULL
,	NULL
N.Y.	NULL
)	NULL
,	NULL
isolated	NULL
by	NULL
using	NULL
a	NULL
magnet	NULL
(	NULL
Advanced	NULL
Magnetics	NULL
Inc.	NULL
,	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

,	NULL
and	NULL
irradiated	NULL
with	NULL
3,000	NULL
rads	NULL
.	NULL

A.E7	NULL
cells	NULL
(	NULL
50	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
25	NULL
x	NULL
10°	NULL
bead-loaded	NULL
DCEK	NULL
cells	NULL
and	NULL
10	NULL
uM	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
(	NULL
CNBr	NULL
fragment	NULL
81-104	NULL
)	NULL
in	NULL
20	NULL
ml	NULL
of	NULL
A.E7	NULL
medium	NULL
in	NULL
an	NULL
upright	NULL
80-cm	NULL
flask	NULL
(	NULL
Nunc	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
pipetted	NULL
vigorously	NULL
to	NULL
obtain	NULL
a	NULL
single-cell	NULL
suspension	NULL
,	NULL
and	NULL
fractionated	NULL
by	NULL
using	NULL
a	NULL
magnet	NULL
which	NULL
yielded	NULL
a	NULL
cell	NULL
population	NULL
that	NULL
consisted	NULL
of	NULL
>	NULL
99	NULL
%	NULL
A.E7	NULL
cells	NULL
.	NULL

Treatment	NULL
with	NULL
ionomycin	NULL
(	NULL
2	NULL
M	NULL
)	NULL
and/or	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
was	NULL
done	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
as	NULL
the	NULL
antigen	NULL
treatments	NULL
,	NULL
except	NULL
that	NULL
no	NULL
DCEK	NULL
cells	NULL
were	NULL
used	NULL
.	NULL

CsA	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Sandoz	NULL
Pharmaceuticals	NULL
)	NULL
was	NULL
used	NULL
at	NULL
200	NULL
ng/ml	NULL
.	NULL

Treatment	NULL
with	NULL
anisomycin	NULL
(	NULL
10	NULL
mM	NULL
)	NULL
was	NULL
begun	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
antigen	NULL
stimulation	NULL
.	NULL

EMSA	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
)	NULL
,	NULL
by	NULL
using	NULL
2	NULL
pug	NULL
of	NULL
nuclear	NULL
extract	NULL
(	NULL
16	NULL
)	NULL
or	NULL
whole-cell	NULL
extract	NULL
(	NULL
19	NULL
)	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

The	NULL
radiolabelled	NULL
oligonucleotide	NULL
probes	NULL
used	NULL
were	NULL
derived	NULL
from	NULL
an	NULL
Igx	NULL
promoter	NULL
,	NULL
either	NULL
wild	NULL
type	NULL
or	NULL
mutated	NULL
in	NULL
all	NULL
base	NULL
pairs	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
(	NULL
19	NULL
)	NULL
,	NULL
or	NULL
the	NULL
mouse	NULL
IL-2	NULL
promoter	NULL
NF-IL-2A	NULL
region	NULL
with	NULL
the	NULL
following	NULL
sequence	NULL
:	NULL
5'TCGAGAAAATATGTGTAATATGTAAAACATCGT3	NULL
'	NULL
3'CTTTTATACACATTATACATTTTGTAGCAAGCTS	NULL
'	NULL
Rabbit	NULL
anti-Oct-2	NULL
serum	NULL
was	NULL
prepared	NULL
by	NULL
immunizing	NULL
rabbits	NULL
with	NULL
the	NULL
peptide	NULL
EAEKQGLDSPSEHTDTERN	NULL
(	NULL
de-rived	NULL
from	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
human	NULL
Oct-2	NULL
,	NULL
outside	NULL
of	NULL
the	NULL
POU	NULL
domain	NULL
)	NULL
coupled	NULL
to	NULL
thyroglobulin	NULL
.	NULL

One	NULL
microliter	NULL
of	NULL
undiluted	NULL
antiserum	NULL
was	NULL
premixed	NULL
with	NULL
extract	NULL
and	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
remaining	NULL
components	NULL
of	NULL
the	NULL
binding	NULL
reaction	NULL
were	NULL
then	NULL
added	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
loading	NULL
on	NULL
a	NULL
nondenaturing	NULL
polyacrylamide	NULL
ge	NULL
!	NULL

as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
prepared	NULL
by	NULL
using	NULL
RNAzo	NULL
!	NULL

(	NULL
Cinna/Biotexc	NULL
,	NULL
Friendswood	NULL
,	NULL
Tex	NULL
.	NULL
)	NULL

in	NULL
accordance	NULL
with	NULL
the	NULL
manufacturer	NULL
's	NULL
protocols	NULL
and	NULL
analyzed	NULL
on	NULL
Northern	NULL
(	NULL
RNA	NULL
)	NULL
blots	NULL
(	NULL
20	NULL
)	NULL
or	NULL
by	NULL
RNase	NULL
protection	NULL
assay	NULL
(	NULL
1	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

Northern	NULL
blots	NULL
were	NULL
hybridized	NULL
with	NULL
mouse	NULL
actin	NULL
cDNA	NULL
probes	NULL
radiolabelled	NULL
by	NULL
the	NULL
random-hexanucleotide	NULL
priming	NULL
method	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
template	NULL
used	NULL
to	NULL
prepare	NULL
the	NULL
radiolabelled	NULL
RNA	NULL
probe	NULL
for	NULL
the	NULL
Oct-2	NULL
RNase	NULL
protection	NULL
assay	NULL
was	NULL
constructed	NULL
by	NULL
blunting	NULL
the	NULL
360-bp	NULL
TikIII1-HindIII	NULL
fragment	NULL
of	NULL
mouse	NULL
Oct-2	NULL
cDNA	NULL
(	NULL
9	NULL
)	NULL
and	NULL
ligating	NULL
it	NULL
into	NULL
the	NULL
Smal	NULL
site	NULL
of	NULL
pGEM3Z	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
.	NULL

The	NULL
template	NULL
was	NULL
linearized	NULL
with	NULL
HindIII	NULL
and	NULL
transcribed	NULL
by	NULL
using	NULL
T7	NULL
RNA	NULL
polymerase	NULL
(	NULL
Promega	NULL
)	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL	NULL
.	NULL

Quantitations	NULL
.	NULL

Radioactivity	NULL
in	NULL
bands	NULL
on	NULL
EMSAs	NULL
,	NULL
Northern	NULL
blots	NULL
,	NULL
and	NULL
RNase	NULL
protection	NULL
assays	NULL
was	NULL
directly	NULL
measured	NULL
by	NULL
using	NULL
a	NULL
Phosphorimager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
Oct-2	NULL
protein	NULL
in	NULL
highly	NULL
purified	NULL
human	NULL
and	NULL
mouse	NULL
T-cell	NULL
preparations	NULL
was	NULL
investigated	NULL
by	NULL
using	NULL
an	NULL
EMSA	NULL
with	NULL
a	NULL
radiolabelled	NULL
oligonucleotide	NULL
probe	NULL
containing	NULL
an	NULL
octamer	NULL
DNA	NULL
motif	NULL
.	NULL

Extracts	NULL
from	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
purified	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
and	NULL
mouse	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
contained	NULL
DNA-binding	NULL
activities	NULL
indistinguishable	NULL
in	NULL
migration	NULL
from	NULL
those	NULL
of	NULL
the	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
proteins	NULL
present	NULL
in	NULL
an	NULL
extract	NULL
of	NULL
the	NULL
B-cell	NULL
line	NULL
WEHI	NULL
231	NULL
.	NULL

Neither	NULL
Oct-1	NULL
nor	NULL
Oct-2	NULL
bands	NULL
were	NULL
seen	NULL
with	NULL
T-cell	NULL
extracts	NULL
when	NULL
a	NULL
probe	NULL
in	NULL
which	NULL
the	NULL
octamer	NULL
motif	NULL
was	NULL
mutated	NULL
was	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lane	NULL
4	NULL
,	NULL
and	NULL
1C	NULL
,	NULL
lane	NULL
2	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
Oct-2	NULL
bands	NULL
from	NULL
the	NULL
mouse	NULL
and	NULL
human	NULL
T-cell	NULL
extracts	NULL
were	NULL
inhibited	NULL
by	NULL
addition	NULL
of	NULL
anti-Oct-2	NULL
serum	NULL
to	NULL
the	NULL
binding	NULL
reactions	NULL
,	NULL
and	NULL
a	NULL
new	NULL
band	NULL
with	NULL
slower	NULL
mobility	NULL
was	NULL
generated	NULL
which	NULL
represents	NULL
the	NULL
binding	NULL
of	NULL
Oct-2	NULL
to	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
1B	NULL
,	NULL
lane	NULL
8	NULL
,	NULL
and	NULL
1C	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
anti-Oct-2	NULL
serum	NULL
used	NULL
was	NULL
specific	NULL
for	NULL
a	NULL
peptide	NULL
derived	NULL
from	NULL
a	NULL
region	NULL
of	NULL
Oct-2	NULL
that	NULL
is	NULL
not	NULL
conserved	NULL
among	NULL
other	NULL
POU	NULL
domain	NULL
transcription	NULL
factors	NULL
.	NULL

Thus	NULL
,	NULL
by	NULL
immunologic	NULL
and	NULL
biochemical	NULL
criteria	NULL
,	NULL
nontransformed	NULL
human	NULL
and	NULL
mouse	NULL
T	NULL
cells	NULL
express	NULL
Oct-2	NULL
protein	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
Oct-2	NULL
could	NULL
be	NULL
induced	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
a	NULL
cognate	NULL
antigen	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
study	NULL
a	NULL
nontransformed	NULL
murine	NULL
T-cell	NULL
clone	NULL
,	NULL
A.E7	NULL
,	NULL
which	NULL
resEonds	NULL
to	NULL
a	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
peptide	NULL
in	NULL
the	NULL
context	NULL
of	NULL
I-E	NULL
``	NULL
(	NULL
11	NULL
)	NULL
.	NULL

We	NULL
prepared	NULL
nuclear	NULL
extracts	NULL
from	NULL
A.E7	NULL
cells	NULL
at	NULL
various	NULL
times	NULL
after	NULL
antigen	NULL
stimulation	NULL
and	NULL
assayed	NULL
them	NULL
for	NULL
octamer-binding	NULL
proteins	NULL
by	NULL
EMSAs	NULL
using	NULL
a	NULL
radiolabelled	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-IL-2A	NULL
sequence	NULL
from	NULL
the	NULL
mouse	NULL
IL-2	NULL
gene	NULL
.	NULL

Binding	NULL
activities	NULL
which	NULL
comigrated	NULL
with	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
were	NULL
observed	NULL
when	NULL
extracts	NULL
from	NULL
resting	NULL
and	NULL
antigen-stimulated	NULL
A.E7	NULL
cells	NULL
were	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Fur-thermore	NULL
,	NULL
both	NULL
resting	NULL
and	NULL
activated	NULL
A.E7	NULL
cells	NULL
expressed	NULL
Oct-2	NULL
protein	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
reactivity	NULL
with	NULL
an	NULL
antiserum	NULL
specific	NULL
for	NULL
Oct-2	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Following	NULL
antigen	NULL
stimulation	NULL
,	NULL
Oct-2-binding	NULL
activity	NULL
was	NULL
slightly	NULL
increased	NULL
at	NULL
3	NULL
h	NULL
and	NULL
markedly	NULL
increased	NULL
at	NULL
9	NULL
and	NULL
24	NULL
h	NULL
after	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
separate	NULL
experi-ments	NULL
,	NULL
Oct-2	NULL
was	NULL
not	NULL
induced	NULL
detectably	NULL
at	NULL
1.5	NULL
h	NULL
poststim-ulation	NULL
but	NULL
did	NULL
increase	NULL
progressively	NULL
in	NULL
abundance	NULL
from	NULL
3	NULL
to	NULL
9	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Maximal	NULL
levels	NULL
of	NULL
Oct-2	NULL
were	NULL
observed	NULL
at	NULL
9	NULL
h	NULL
following	NULL
activation	NULL
and	NULL
were	NULL
sixfold	NULL
greater	NULL
than	NULL
resting	NULL
levels	NULL
.	NULL

The	NULL
abundance	NULL
of	NULL
Oct-2	NULL
in	NULL
activated	NULL
A.E7	NULL
cells	NULL
approached	NULL
that	NULL
of	NULL
the	NULL
BJAB	NULL
B-cell	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
expresses	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
Oct-2	NULL
found	NULL
in	NULL
any	NULL
cell	NULL
line	NULL
analyzed	NULL
to	NULL
date	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
compare	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Oct-2	NULL
levels	NULL
,	NULL
Oct-1	NULL
levels	NULL
increased	NULL
less	NULL
than	NULL
twofold	NULL
following	NULL
antigen	NULL
stimulation	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
continued	NULL
antigen	NULL
stimulation	NULL
was	NULL
necessary	NULL
for	NULL
this	NULL
increase	NULL
in	NULL
Oct-2	NULL
,	NULL
we	NULL
separated	NULL
the	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
antigen	NULL
and	NULL
APCs	NULL
after	NULL
3	NULL
h	NULL
of	NULL
stimulation	NULL
,	NULL
placed	NULL
them	NULL
back	NULL
in	NULL
culture	NULL
,	NULL
and	NULL
prepared	NULL
extracts	NULL
at	NULL
various	NULL
times	NULL
thereafter	NULL
.	NULL

Oct-2	NULL
levels	NULL
continued	NULL
to	NULL
increase	NULL
over	NULL
time	NULL
in	NULL
T	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
removed	NULL
from	NULL
the	NULL
antigen	NULL
stimulus	NULL
at	NULL
3	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
with	NULL
many	NULL
other	NULL
events	NULL
following	NULL
T-cell	NULL
activation	NULL
,	NULL
all	NULL
of	NULL
the	NULL
signals	NULL
necessary	NULL
for	NULL
Oct-2	NULL
induction	NULL
were	NULL
delivered	NULL
within	NULL
the	NULL
first	NULL
few	NULL
hours	NULL
of	NULL
activation	NULL
(	NULL
31	NULL
)	NULL
.	NULL

T-cell	NULL
activation	NULL
via	NULL
stimulation	NULL
through	NULL
a	NULL
T-cell	NULL
receptor	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
Oct-2	NULL
INDUCTION	NULL
IN	NULL
ANTIGEN-SPECIFIC	NULL
T-CELL	NULL
ACTIVATION	NULL
3151	NULL
A	NULL
§	NULL
&	NULL
B	NULL
faeyrgs	NULL
,	NULL
§§	NULL
.	NULL

noel	NULL
ase	NULL
&	NULL
]	NULL
s	NULL
<	NULL
|-	NULL
hak	NULL
|	NULL
~	NULL
c	NULL
up	NULL
-	NULL
Cell	NULL
Type	NULL
ell	NULL
Type	NULL
$	NULL
gC	NULL
-g	NULL
CeIIType	NULL
:	NULL
5	NULL
$	NULL
33	NULL
a	NULL
CeIITypeafgf	NULL
;	NULL
>	NULL
$	NULL
588	NULL
4	NULL
88g	NULL
a	NULL
|	NULL
SSS	NULL
0	NULL
0	NULL
o	NULL
=	NULL
o	NULL
S	NULL
8	NULL
sso	NULL
0	NULL
.	NULL

(	NULL
er	NULL
~	NULL
ea	NULL
A	NULL
(	NULL
x	NULL
Probe	NULL
:	NULL
E	NULL
5	NULL
p	NULL
tz	NULL
-	NULL
s	NULL
robe	NULL
(	NULL
,	NULL
.	NULL

2	NULL
Probe~§	NULL
E55	NULL
oo	NULL
98	NULL
”	NULL
Am	NULL
‘	NULL
b°dv	NULL
[	NULL
§	NULL
§	NULL
z	NULL
.	NULL

Antibody	NULL
-	NULL
o	NULL
8	NULL
o	NULL
(	NULL
<	NULL
3	NULL
:	NULL
(	NULL
55	NULL
L	NULL
a	NULL
3	NULL
a	NULL
3a	NULL
3_	NULL
L	NULL
-5	NULL
#	NULL
s	NULL
<	NULL
-Oct-2	NULL
+	NULL
Ab	NULL
<	NULL
-	NULL
Oct-2	NULL
+	NULL
Ab	NULL
Oct-2	NULL
+	NULL
Ab	NULL
-	NULL
hae	NULL
Oct-1	NULL
-	NULL
>	NULL
<	NULL
-Oct-1	NULL
%	NULL
ao	NULL
:	NULL
y	NULL
Oct-2	NULL
~	NULL
``	NULL
``	NULL
*	NULL
-Oct-2	NULL
get-1	NULL
#	NULL
s	NULL
:	NULL
Oct-1	NULL
@	NULL
m	NULL
-	NULL
``	NULL
)	NULL
@	NULL
a.	NULL
ct2	NULL
~	NULL
>	NULL
W	NULL
Oct-1	NULL
-	NULL
s=	NULL
ti	NULL
W	NULL
D	NULL
|	NULL
6	NULL
wow	NULL
Oct-2	NULL
-	NULL
ﬁg	NULL
#	NULL
@	NULL
®	NULL
.	NULL

K	NULL
11	NULL
2G	NULL
4	NULL
“	NULL
n	NULL
5	NULL
6	NULL
78	NULL
<	NULL
e	NULL
4	NULL
1	NULL
28	NULL
Te	NULL
-Pi	NULL
32	NULL
4s	NULL
5	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Expression	NULL
of	NULL
Oct-2	NULL
protein	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
of	NULL
whole-cell	NULL
extracts	NULL
prepared	NULL
from	NULL
human	NULL
CD4*	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
or	NULL
WEHI	NULL
231	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
using	NULL
the	NULL
radiolabelled	NULL
Igx	NULL
promoter	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

Extracts	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
preimmune	NULL
rabbit	NULL
serum	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
antiserum	NULL
from	NULL
a	NULL
rabbit	NULL
immunized	NULL
with	NULL
a	NULL
synthetic	NULL
peptide	NULL
based	NULL
on	NULL
the	NULL
human	NULL
Oct-2	NULL
sequence	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Lane	NULL
5	NULL
is	NULL
a	NULL
longer	NULL
exposure	NULL
of	NULL
lane	NULL
4	NULL
.	NULL

Ab	NULL
,	NULL
antibody	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
of	NULL
whole-cell	NULL
extracts	NULL
of	NULL
human	NULL
CD8*	NULL
T	NULL
cells	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
or	NULL
WEHI	NULL
231	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
using	NULL
either	NULL
a	NULL
radiolabelled	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
Igx	NULL
promoter	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
5	NULL
to	NULL
8	NULL
)	NULL
or	NULL
a	NULL
mutant	NULL
(	NULL
MUT	NULL
)	NULL
Igx	NULL
promoter	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Extracts	NULL
were	NULL
mixed	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
or	NULL
anti-Oct-2	NULL
serum	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
8	NULL
,	NULL
the	NULL
band	NULL
representing	NULL
Oct-2	NULL
complexed	NULL
with	NULL
antibody	NULL
is	NULL
faint	NULL
but	NULL
comigrated	NULL
with	NULL
the	NULL
corresponding	NULL
band	NULL
seen	NULL
when	NULL
WEHI	NULL
231	NULL
extract	NULL
was	NULL
used	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
of	NULL
whole-cell	NULL
extracts	NULL
of	NULL
mouse	NULL
mesenteric	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
WEHI	NULL
231	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
using	NULL
either	NULL
a	NULL
radiolabelled	NULL
wild-type	NULL
Igx	NULL
promoter	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
)	NULL
or	NULL
a	NULL
mutant	NULL
Ig	NULL
«	NULL
x	NULL
promoter	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
lane	NULL
4	NULL
reaction	NULL
contained	NULL
anti-Oct-2	NULL
serum	NULL
.	NULL

has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
at	NULL
least	NULL
partly	NULL
mediated	NULL
by	NULL
calcium	NULL
mobilization	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
,	NULL
a	NULL
process	NULL
that	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
treatment	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
(	NULL
3	NULL
,	NULL
17	NULL
,	NULL
21	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
studied	NULL
the	NULL
signal	NULL
requirements	NULL
for	NULL
Oct-2	NULL
activation	NULL
in	NULL
A.E7	NULL
cells	NULL
.	NULL

Oct-2	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
PMA	NULL
alone	NULL
and	NULL
only	NULL
slightly	NULL
induced	NULL
by	NULL
ionomycin	NULL
alone	NULL
but	NULL
was	NULL
induced	NULL
eightfold	NULL
by	NULL
ionomycin	NULL
and	NULL
PMA	NULL
together	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

We	NULL
next	NULL
investigated	NULL
whether	NULL
induction	NULL
of	NULL
Oct-2-binding	NULL
activity	NULL
in	NULL
A.E7	NULL
was	NULL
due	NULL
to	NULL
a	NULL
posttranslational	NULL
modification	NULL
of	NULL
pre-existing	NULL
Oct-2	NULL
protein	NULL
or	NULL
to	NULL
accumulation	NULL
of	NULL
Oct-2	NULL
mRNA	NULL
.	NULL

An	NULL
RNase	NULL
protection	NULL
assay	NULL
for	NULL
Oct-2	NULL
mRNA	NULL
showed	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
Oct-2	NULL
mRNA	NULL
in	NULL
resting	NULL
A.E7	NULL
cells	NULL
,	NULL
which	NULL
increased	NULL
12-	NULL
and	NULL
28-fold	NULL
after	NULL
3	NULL
and	NULL
6	NULL
h	NULL
of	NULL
antigen	NULL
stimulation	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
Oct-2	NULL
mRNA	NULL
was	NULL
almost	NULL
completely	NULL
blocked	NULL
by	NULL
addition	NULL
of	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
and	NULL
partially	NULL
blocked	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
anisomycin	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
Oct-2-binding	NULL
activity	NULL
in	NULL
an	NULL
EMSA	NULL
was	NULL
also	NULL
blocked	NULL
by	NULL
treatment	NULL
with	NULL
CsA	NULL
or	NULL
anisomycin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
report	NULL
demonstrates	NULL
that	NULL
Oct-2	NULL
is	NULL
expressed	NULL
in	NULL
normal	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
lymphocytes	NULL
and	NULL
that	NULL
Oct-2	NULL
levels	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
their	NULL
cognate	NULL
antigen	NULL
.	NULL

Previous	NULL
studies	NULL
of	NULL
Oct-2	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
hematopoietic	NULL
system	NULL
focusing	NULL
on	NULL
transformed	NULL
cell	NULL
lines	NULL
have	NULL
shown	NULL
Oct-2	NULL
in	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
B-	NULL
and	NULL
T-lym-phoid	NULL
,	NULL
myeloid	NULL
,	NULL
and	NULL
erythroid	NULL
lineages	NULL
(	NULL
5	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Outside	NULL
of	NULL
the	NULL
hematopoietic	NULL
system	NULL
,	NULL
Oct-2	NULL
mRNA	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
fetal	NULL
spinal	NULL
cord	NULL
,	NULL
in	NULL
adult	NULL
brain	NULL
,	NULL
and	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
a	NULL
few	NULL
other	NULL
tissues	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Quantitatively	NULL
,	NULL
however	NULL
,	NULL
Oct-2	NULL
levels	NULL
vary	NULL
greatly	NULL
but	NULL
are	NULL
generally	NULL
much	NULL
higher	NULL
in	NULL
B-cell	NULL
lines	NULL
than	NULL
in	NULL
other	NULL
cell	NULL
lines	NULL
(	NULL
5	NULL
,	NULL
21	NULL
,	NULL
25	NULL
)	NULL
.	NULL

An	NULL
important	NULL
observation	NULL
in	NULL
the	NULL
present	NULL
study	NULL
,	NULL
therefore	NULL
,	NULL
is	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
Oct-2	NULL
protein	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
as	NULL
high	NULL
as	NULL
those	NULL
found	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
Oct-2	NULL
protein	NULL
induced	NULL
in	NULL
the	NULL
A.E7	NULL
normal	NULL
T-cell	NULL
clone	NULL
by	NULL
stimulation	NULL
with	NULL
antigen	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
approached	NULL
the	NULL
highest	NULL
levels	NULL
seen	NULL
in	NULL
any	NULL
B-cell	NULL
tumor	NULL
line	NULL
.	NULL

Some	NULL
transcriptional	NULL
responses	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
behave	NULL
nonlinearly	NULL
in	NULL
that	NULL
only	NULL
after	NULL
the	NULL
level	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
exceeds	NULL
a	NULL
threshold	NULL
is	NULL
any	NULL
transcription	NULL
stimulation	NULL
observed	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
Oct-2	NULL
expression	NULL
found	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
could	NULL
conceivably	NULL
fall	NULL
below	NULL
a	NULL
functional	NULL
threshold	NULL
whereas	NULL
the	NULL
higher	NULL
levels	NULL
found	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
certain	NULL
T	NULL
cells	NULL
could	NULL
be	NULL
functionally	NULL
signifi-cant	NULL
.	NULL

An	NULL
interesting	NULL
unresolved	NULL
issue	NULL
is	NULL
whether	NULL
T	NULL
cells	NULL
which	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
Oct-2	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
A.E7	NULL
)	NULL
are	NULL
functionally	NULL
or	NULL
developmentally	NULL
distinct	NULL
from	NULL
T	NULL
cells	NULL
which	NULL
do	NULL
not	NULL
express	NULL
Oct-2	NULL
(	NULL
as	NULL
represented	NULL
by	NULL
the	NULL
Jurkat	NULL
T-lymphoma	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

What	NULL
might	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
Oct-2	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
be	NULL
?	NULL

Previously	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
EL4	NULL
T-cell	NULL
line	NULL
,	NULL
which	NULL
expresses	NULL
high	NULL
levels	NULL
of	NULL
Oct-2	NULL
,	NULL
requires	NULL
only	NULL
PMA	NULL
treatment	NULL
to	NULL
induce	NULL
IL-2	NULL
promoter	NULL
activity	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Simi-	NULL
3152	NULL
KANG	NULL
ET	NULL
AL	NULL
.	NULL

Cell	NULL
Type	NULL
<	NULL
AE7	NULL
AE7	NULL
AE7	NULL
AE7	NULL
AE7Z	NULL
AE7Z	NULL
BJAB	NULL
NT2	NULL
I	NULL
Harvest	NULL
Time	NULL
<	NULL
hr	NULL
24	NULL
hr	NULL
9	NULL
0	NULL
h	NULL
3	NULL
hr	NULL
hr	NULL
24	NULL
hr	NULL
Treatment	NULL
£2	NULL
:	NULL
'It	NULL
``	NULL
L2	NULL
C.	NULL
k	NULL
.C	NULL
8000000	NULL
£0	NULL
Of	NULL
0g	NULL
o	NULL
u	NULL
1	NULL
u	NULL
2	NULL
4T	NULL
T	NULL
TI	NULL
a*	NULL
&	NULL
-	NULL
Ag-24	NULL
hr	NULL
.	NULL

@	NULL
-	NULL
Ag-9	NULL
hr	NULL
.	NULL

Oct-1	NULL
-	NULL
>	NULL
Oct-2	NULL
-	NULL
>	NULL
1-203	NULL
©4	NULL
G.-0G	NULL
ZB	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Induction	NULL
of	NULL
Oct-2	NULL
protein	NULL
following	NULL
antigenic	NULL
stimulation	NULL
of	NULL
A.E7	NULL
T	NULL
cells	NULL
.	NULL

EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
A.E7	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
6	NULL
)	NULL
exposed	NULL
for	NULL
various	NULL
times	NULL
(	NULL
Treatment	NULL
)	NULL
to	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
peptide	NULL
and	NULL
APCs	NULL
and	NULL
harvested	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
(	NULL
Harvest	NULL
Time	NULL
)	NULL
.	NULL

The	NULL
NF-IL-2A	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
the	NULL
radiolabelled	NULL
probe	NULL
.	NULL

Ag	NULL
,	NULL
antigen	NULL
.	NULL

larly	NULL
,	NULL
transfection	NULL
of	NULL
Oct-2	NULL
expression	NULL
vectors	NULL
into	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
allows	NULL
the	NULL
IL-2	NULL
promoter	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
PMA	NULL
treatment	NULL
alone	NULL
(	NULL
13	NULL
)	NULL
.	NULL

An	NULL
interesting	NULL
possibility	NULL
,	NULL
therefore	NULL
,	NULL
is	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
Oct-2	NULL
in	NULL
T	NULL
cells	NULL
functionally	NULL
substitutes	NULL
,	NULL
in	NULL
part	NULL
,	NULL
for	NULL
a	NULL
calcium	NULL
signal	NULL
that	NULL
is	NULL
usually	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
many	NULL
genes	NULL
following	NULL
T-cell	NULL
activation	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
which	NULL
express	NULL
Oct-2	NULL
,	NULL
some	NULL
genes	NULL
might	NULL
respond	NULL
differently	NULL
to	NULL
T-cell	NULL
activation	NULL
signals	NULL
from	NULL
the	NULL
way	NULL
they	NULL
do	NULL
in	NULL
T	NULL
cells	NULL
which	NULL
lack	NULL
Oct-2	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
inducibility	NULL
of	NULL
Oct-2	NULL
protein	NULL
in	NULL
A.E7	NULL
cells	NULL
contributes	NULL
to	NULL
early	NULL
transcriptional	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

In	NULL
A.E7	NULL
cells	NULL
,	NULL
initial	NULL
induction	NULL
of	NULL
IL-2	NULL
mRNA	NULL
begins	NULL
at	NULL
1	NULL
h	NULL
following	NULL
activation	NULL
,	NULL
well	NULL
before	NULL
the	NULL
first	NULL
detectable	NULL
increase	NULL
in	NULL
Oct-2	NULL
protein	NULL
(	NULL
13b	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
IL-2	NULL
is	NULL
induced	NULL
in	NULL
many	NULL
T	NULL
cells	NULL
(	NULL
exemplified	NULL
by	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
)	NULL
which	NULL
lack	NULL
readily	NULL
detectable	NULL
Oct-2	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bror	NULL
.	NULL

[	NULL
C	NULL
WEHI	NULL
Cell	NULL
Type	NULL
I	NULL
AE7	NULL
234	NULL
=	NULL
1	NULL
<	NULL
1T	NULL
71	NULL
a	NULL
>	NULL
A_	NULL
Treatment	NULL
o	NULL
.	NULL
)	NULL

'	NULL
@	NULL
S	NULL
|	NULL
il	NULL
$	NULL
m	NULL
e	NULL
pe	NULL
gece	NULL
Antbed	NULL
y	NULL
yig	NULL
|	NULL
y	NULL
}	NULL
:	NULL
-	NULL
ily	NULL
n|	NULL
44	NULL
+4	NULL
OCT	NULL
s	NULL
&	NULL
vae	NULL
v	NULL
be	NULL
a	NULL
28	NULL
a	NULL
2	NULL
L	NULL
L	NULL
$	NULL
L	NULL
yk	NULL
©	NULL
L	NULL
8	NULL
L	NULL
S	NULL
¥	NULL
**	NULL
ws	NULL
C	NULL
J	NULL
®	NULL
®	NULL
r	NULL
%	NULL
#	NULL
*	NULL
Oct-2+Ab	NULL
-	NULL
»	NULL
Oct-1-	NULL
»	NULL
Oct-2-	NULL
»	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Induction	NULL
of	NULL
Oct-2	NULL
protein	NULL
by	NULL
treatment	NULL
of	NULL
A.E7	NULL
T	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Iono	NULL
)	NULL
.	NULL

EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
resting	NULL
A.E7	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
from	NULL
A.E7	NULL
cells	NULL
stimulated	NULL
for	NULL
11	NULL
h	NULL
with	NULL
ionomycin	NULL
(	NULL
lane	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
treatments	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
or	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
antigen	NULL
(	NULL
Ag	NULL
)	NULL
and	NULL
APCs	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
NF-IL-2A	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
the	NULL
radiolabelled	NULL
probe	NULL
.	NULL

Extracts	NULL
were	NULL
mixed	NULL
with	NULL
either	NULL
preimmune	NULL
serum	NULL
(	NULL
odd-numbered	NULL
lanes	NULL
)	NULL
or	NULL
anti-Oct-2	NULL
serum	NULL
(	NULL
even-numbered	NULL
lanes	NULL
)	NULL
.	NULL

Ab	NULL
,	NULL
antibody	NULL
.	NULL

the	NULL
octamer-containing	NULL
NF-IL-2A	NULL
site	NULL
in	NULL
these	NULL
cells	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
cooperative	NULL
binding	NULL
of	NULL
Oct-l	NULL
to	NULL
this	NULL
element	NULL
with	NULL
an	NULL
inducible	NULL
protein	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
light	NULL
of	NULL
the	NULL
extensive	NULL
homology	NULL
of	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
in	NULL
their	NULL
POU	NULL
do-mains	NULL
,	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
test	NULL
whether	NULL
Oct-2	NULL
can	NULL
also	NULL
interact	NULL
with	NULL
the	NULL
same	NULL
inducible	NULL
protein	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
cognate	NULL
antigen	NULL
or	NULL
pharmacologic	NULL
agents	NULL
results	NULL
in	NULL
the	NULL
induced	NULL
expression	NULL
of	NULL
a	NULL
large	NULL
array	NULL
of	NULL
genes	NULL
(	NULL
31	NULL
)	NULL
.	NULL

This	NULL
highly	NULL
ordered	NULL
program	NULL
of	NULL
gene	NULL
expression	NULL
begins	NULL
within	NULL
15	NULL
min	NULL
of	NULL
activation	NULL
with	NULL
expression	NULL
of	NULL
the	NULL
immediate-early	NULL
family	NULL
of	NULL
genes	NULL
.	NULL

Subse-quently	NULL
,	NULL
various	NULL
genes	NULL
are	NULL
expressed	NULL
with	NULL
characteristic	NULL
time	NULL
courses	NULL
over	NULL
several	NULL
days	NULL
to	NULL
weeks	NULL
.	NULL

The	NULL
increased	NULL
expression	NULL
of	NULL
many	NULL
of	NULL
these	NULL
T-cell	NULL
activation	NULL
genes	NULL
is	NULL
due	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
increased	NULL
transcription	NULL
.	NULL

Several	NULL
of	NULL
the	NULL
immediate-early	NULL
activation	NULL
genes	NULL
are	NULL
themselves	NULL
transcription	NULL
factors	NULL
which	NULL
are	NULL
presumed	NULL
to	NULL
transactivate	NULL
other	NULL
genes	NULL
in	NULL
a	NULL
cascade	NULL
fashion	NULL
.	NULL

Since	NULL
the	NULL
immediate-early	NULL
transcription	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
Cell	NULL
Type	NULL
;	NULL
im	NULL
&	NULL
Go	NULL
G	NULL
im	NULL
&	NULL
P	NULL
<	NULL
-E	NULL
5	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
&	NULL
s	NULL
&	NULL
Harvest	NULL
Txme	NULL
{	NULL
re	NULL
£	NULL
``	NULL
£1	NULL
<	NULL
£	NULL
£	NULL
E	NULL
|	NULL
o	NULL
o	NULL
w	NULL
o	NULL
w	NULL
co	NULL
w	NULL
o	NULL
o	NULL
<	NULL
<	NULL
2	NULL
2	NULL
C	NULL
w	NULL
C	NULL
C	NULL
Treatment	NULL
o	NULL
o	NULL
<	NULL
<	NULL
A	NULL
o	NULL
+	NULL
+	NULL
+	NULL
+	NULL
|	NULL
6	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
u	NULL
=	NULL
T	NULL
<	NULL
<	NULL
<	NULL
T	NULL
<	NULL
Oct-2-	NULL
»	NULL
@	NULL
&	NULL
ic	NULL
--	NULL
OB	NULL
UBL	NULL
I®	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Induction	NULL
of	NULL
Oct-2	NULL
mRNA	NULL
by	NULL
antigen	NULL
(	NULL
Ag	NULL
)	NULL
activation	NULL
of	NULL
A.E7	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
Top	NULL
panel	NULL
)	NULL
RNase	NULL
protection	NULL
assay	NULL
of	NULL
total	NULL
RNA	NULL
(	NULL
20	NULL
g	NULL
)	NULL
prepared	NULL
from	NULL
A.E7	NULL
cells	NULL
treated	NULL
in	NULL
the	NULL
following	NULL
ways	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
untreated	NULL
;	NULL
lanes	NULL
2	NULL
to	NULL
7	NULL
,	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
peptide	NULL
plus	NULL
APCs	NULL
for	NULL
3	NULL
h	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
)	NULL
or	NULL
6	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
h	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
CsA	NULL
;	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
,	NULL
anisomycin	NULL
(	NULL
Anis	NULL
.	NULL
)	NULL

.	NULL

(	NULL
Bottom	NULL
panel	NULL
)	NULL
Northern	NULL
blot	NULL
of	NULL
A.E7	NULL
RNA	NULL
preparations	NULL
(	NULL
10	NULL
g	NULL
)	NULL
identical	NULL
to	NULL
those	NULL
used	NULL
for	NULL
the	NULL
top	NULL
panel	NULL
hybridized	NULL
with	NULL
a	NULL
radiolabelled	NULL
mouse	NULL
actin	NULL
cDNA	NULL
probe	NULL
.	NULL

¢	NULL
9	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
c-fos	NULL
(	NULL
18	NULL
)	NULL
and	NULL
Egr/225	NULL
(	NULL
32	NULL
)	NULL
,	NULL
are	NULL
often	NULL
rapidly	NULL
down	NULL
modulated	NULL
following	NULL
their	NULL
induction	NULL
,	NULL
they	NULL
can	NULL
not	NULL
directly	NULL
transactivate	NULL
genes	NULL
which	NULL
are	NULL
induced	NULL
many	NULL
hours	NULL
following	NULL
T-cell	NULL
activation	NULL
.	NULL

One	NULL
hypothesis	NULL
,	NULL
therefore	NULL
,	NULL
is	NULL
that	NULL
the	NULL
immediate-early	NULL
transcription	NULL
factors	NULL
turn	NULL
on	NULL
a	NULL
second	NULL
set	NULL
of	NULL
transcription	NULL
factors	NULL
which	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
later	NULL
events	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
relatively	NULL
delayed	NULL
kinetics	NULL
of	NULL
Oct-2	NULL
induction	NULL
suggests	NULL
that	NULL
Oct-2	NULL
is	NULL
such	NULL
a	NULL
downstream	NULL
component	NULL
of	NULL
a	NULL
regulatory	NULL
cascade	NULL
that	NULL
follows	NULL
T-cell	NULL
activation	NULL
.	NULL

Oct-2-binding	NULL
levels	NULL
were	NULL
first	NULL
increased	NULL
at	NULL
3	NULL
h	NULL
following	NULL
stimulation	NULL
with	NULL
a	NULL
cognate	NULL
antigen	NULL
,	NULL
which	NULL
is	NULL
approximately	NULL
the	NULL
same	NULL
time	NULL
course	NULL
as	NULL
is	NULL
seen	NULL
with	NULL
other	NULL
targets	NULL
of	NULL
the	NULL
immediate-early	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Most	NULL
impor-tantly	NULL
,	NULL
Oct-2	NULL
levels	NULL
remained	NULL
induced	NULL
for	NULL
at	NULL
least	NULL
24	NULL
h	NULL
following	NULL
stimulation	NULL
so	NULL
that	NULL
Oct-2	NULL
could	NULL
also	NULL
potentially	NULL
act	NULL
as	NULL
a	NULL
late	NULL
mediator	NULL
of	NULL
T-cell	NULL
activation	NULL
signals	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Bill	NULL
Gause	NULL
and	NULL
Fred	NULL
Steinberg	NULL
for	NULL
help	NULL
in	NULL
the	NULL
initial	NULL
phases	NULL
of	NULL
this	NULL
study	NULL
and	NULL
Ivan	NULL
Horak	NULL
,	NULL
Toshio	NULL
Tanaka	NULL
,	NULL
and	NULL
Ron	NULL
Germain	NULL
for	NULL
reagents	NULL
.	NULL

M.J.L	NULL
.	NULL

and	NULL
L.M.S	NULL
.	NULL

are	NULL
supported	NULL
by	NULL
Cancer	NULL
Research	NULL
Institute	NULL
Investigator	NULL
Awards	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
.	NULL

1987	NULL
.	NULL

Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

2	NULL
.	NULL

Banerji	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
J.	NULL
N.	NULL
Parsons	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Tocci	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
immunosuppressant	NULL
FK-506	NULL
specifically	NULL
inhibits	NULL
mitogen-in-duced	NULL
activation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
and	NULL
the	NULL
isolated	NULL
enhancer	NULL
elements	NULL
NFIL-2A	NULL
and	NULL
NF-AT1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:4074-4087	NULL
.	NULL

3	NULL
.	NULL

Bours	NULL
,	NULL
V.	NULL
,	NULL
J.	NULL
Villalobos	NULL
,	NULL
P.	NULL
R.	NULL
Burd	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
mitogen-inducible	NULL
gene	NULL
encoding	NULL
a	NULL
kappa	NULL
B	NULL
DNA-binding	NULL
protein	NULL
with	NULL
homology	NULL
to	NULL
the	NULL
rel	NULL
oncogene	NULL
and	NULL
to	NULL
cell-cycle	NULL
motifs	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
348:76-80	NULL
.	NULL

4	NULL
.	NULL

Brabletz	NULL
,	NULL
T.	NULL
,	NULL
I.	NULL
Pietrowski	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
immuno-suppressives	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
inhibit	NULL
the	NULL
generation	NULL
of	NULL
protein	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
two	NULL
purine	NULL
boxes	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
enhancer	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:61-67	NULL
.	NULL

Oct-2	NULL
INDUCTION	NULL
IN	NULL
ANTIGEN-SPECIFIC	NULL
T-CELL	NULL
ACTIVATION	NULL
3153	NULL
5	NULL
.	NULL

Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
and	NULL
S.	NULL
P.	NULL
Klinken	NULL
.	NULL

1990	NULL
.	NULL

Octamer-binding	NULL
proteins	NULL
in	NULL
diverse	NULL
hemopoietic	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:1293-1296	NULL
.	NULL

6	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

7	NULL
.	NULL

Fiering	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
P.	NULL
Northrup	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
.	NULL

1990	NULL
.	NULL

Single	NULL
cell	NULL
assay	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
reveals	NULL
a	NULL
threshold	NULL
in	NULL
transcription	NULL
activated	NULL
by	NULL
signals	NULL
emanating	NULL
from	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:1823-1834	NULL
.	NULL

8	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Shibuya	NULL
,	NULL
K.	NULL
Ohashi	NULL
,	NULL
K.	NULL
Yamanishi	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1986	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
:	NULL
functional	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
for	NULL
the	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
46:401-407	NULL
.	NULL

9	NULL
.	NULL

Hatzopoulos	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
A.	NULL
S.	NULL
Stoykova	NULL
,	NULL
J.	NULL
R.	NULL
Erselins	NULL
,	NULL
M.	NULL
Goulding	NULL
,	NULL
T.	NULL
Neuman	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1990	NULL
.	NULL

Structure	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
mouse	NULL
Oct-2a	NULL
and	NULL
Oct-2b	NULL
,	NULL
two	NULL
differentially	NULL
spliced	NULL
products	NULL
of	NULL
the	NULL
same	NULL
gene	NULL
.	NULL

Development	NULL
109:349-362	NULL
.	NULL

10	NULL
.	NULL

He	NULL
,	NULL
X.	NULL
,	NULL
M.	NULL
N.	NULL
Treacy	NULL
,	NULL
D.	NULL
M.	NULL
Simmons	NULL
,	NULL
H.	NULL
A.	NULL
Ingraham	NULL
,	NULL
L.	NULL
W.	NULL
Swanson	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
a	NULL
large	NULL
family	NULL
of	NULL
POU-domain	NULL
regulatory	NULL
genes	NULL
in	NULL
mammalian	NULL
brain	NULL
development	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
340:35-42	NULL
.	NULL

11	NULL
.	NULL

Hecht	NULL
,	NULL
T.	NULL
T.	NULL
,	NULL
D.	NULL
L.	NULL
Longo	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Matis	NULL
.	NULL

1983	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
immune	NULL
interferon	NULL
production	NULL
and	NULL
proliferation	NULL
by	NULL
antigen-specific	NULL
T	NULL
cell	NULL
receptor	NULL
with	NULL
its	NULL
ligands	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

131:1049	NULL
.	NULL

12	NULL
.	NULL

Herr	NULL
,	NULL
W.	NULL
,	NULL
R.	NULL
A.	NULL
Sturm	NULL
,	NULL
R.	NULL
G.	NULL
Clerc	NULL
,	NULL
L.	NULL
M.	NULL
Corcoran	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
H.	NULL
A.	NULL
Ingraham	NULL
,	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
Finney	NULL
,	NULL
G.	NULL
Ruykun	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
Horwitz	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
POU-domain	NULL
:	NULL
a	NULL
large	NULL
conserved	NULL
region	NULL
in	NULL
the	NULL
mammalian	NULL
pit-1	NULL
,	NULL
oct-1	NULL
,	NULL
oct-2	NULL
,	NULL
and	NULL
Caenorhabditis	NULL
elegans	NULL
unc-86	NULL
gene	NULL
products	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:1513-1516	NULL
.	NULL

13	NULL
.	NULL

Kamps	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
L.	NULL
Corcoran	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
gene	NULL
contains	NULL
two	NULL
octamer-binding	NULL
sites	NULL
and	NULL
is	NULL
partially	NULL
activated	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
Oct-2	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:5464-5472	NULL
.	NULL

13a.Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Lenardo	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

13b.Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
A.-C.	NULL
Tran	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Lenardo	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

14	NULL
.	NULL

Kemler	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1990	NULL
.	NULL

Octamer	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
cell	NULL
type-specificity	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

41444-1449	NULL
.	NULL

15	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
K.	NULL
S.	NULL
Ullman	NULL
,	NULL
S.	NULL
Fiering	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
M.	NULL
McCutcheon	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
actions	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:4425-4433	NULL
.	NULL

16	NULL
.	NULL

Ohlsson	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
Edlund	NULL
.	NULL

1986	NULL
.	NULL

Sequence-specific	NULL
interactions	NULL
of	NULL
nuclear	NULL
factors	NULL
with	NULL
the	NULL
insulin	NULL
gene	NULL
enhancer	NULL
.	NULL

Cell	NULL
45:35-44	NULL
.	NULL

17	NULL
.	NULL

Randak	NULL
,	NULL
C.	NULL
,	NULL
T.	NULL
Brabletz	NULL
,	NULL
M.	NULL
Hergenrother	NULL
,	NULL
I.	NULL
Sobotta	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1990	NULL
.	NULL

Cyclosporin	NULL
A	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
by	NULL
inhibiting	NULL
the	NULL
binding	NULL
of	NULL
lymphocyte-specific	NULL
factors	NULL
to	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:2529-2536	NULL
.	NULL

18	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
J.	NULL
D.	NULL
Alpers	NULL
,	NULL
P.	NULL
C.	NULL
Nowell	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Hoover	NULL
.	NULL

1986	NULL
.	NULL

Sequential	NULL
expression	NULL
of	NULL
proto-oncogenes	NULL
during	NULL
lectin-stimu-lated	NULL
mitogenesis	NULL
of	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
$	NULL
3:3982-3986	NULL
.	NULL

19	NULL
.	NULL

Rosner	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
M.	NULL
A.	NULL
Vigano	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
P.	NULL
M.	NULL
Timmons	NULL
,	NULL
F.	NULL
Poirier	NULL
,	NULL
P.	NULL
W.	NULL
J.	NULL
Rigby	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Staudt	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
POU-domain	NULL
transcription	NULL
factor	NULL
in	NULL
early	NULL
stem	NULL
cells	NULL
and	NULL
germ	NULL
cells	NULL
of	NULL
the	NULL
mammalian	NULL
embryo	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
345:686-692	NULL
.	NULL

20	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
21	NULL
.	NULL

Schlissel	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
L.	NULL
M.	NULL
Corcoran	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1991	NULL
.	NULL

Virus-transformed	NULL
pre-B	NULL
cells	NULL
show	NULL
ordered	NULL
activation	NULL
but	NULL
not	NULL
inactivation	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
rearrangement	NULL
and	NULL
transcription	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:711-720	NULL
.	NULL

22	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.	NULL
Muller	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
lymphoid	NULL
specific	NULL
octamer	NULL
binding	NULL
protein	NULL
(	NULL
OTF-2B	NULL
)	NULL
by	NULL
proteolytic	NULL
clipping	NULL
bandshift	NULL
assay	NULL
(	NULL
PCBA	NULL
)	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:4221-4229	NULL
.	NULL

3154	NULL
23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

KANG	NULL
ET	NULL
AL	NULL
.	NULL

Shibuya	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
multiple	NULL
cis-elements	NULL
and	NULL
trans-acting	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
induced	NULL
expression	NULL
of	NULL
human	NULL
IL-2	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:9173-9184	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
N.	NULL
J.	NULL
Holbrook	NULL
,	NULL
C.	NULL
A.	NULL
Norris	NULL
,	NULL
M.	NULL
Kamoun	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1986	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interleukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibility	NULL
on	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:3042-3049	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
R.	NULL
G.	NULL
Clerc	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
lymphoid-specific	NULL
cDNA	NULL
encoding	NULL
a	NULL
protein	NULL
binding	NULL
the	NULL
regulatory	NULL
octamer	NULL
DNA	NULL
motif	NULL
.	NULL

Science	NULL
241:577-580	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Lenardo	NULL
.	NULL

1991	NULL
.	NULL

Immunoglobulin	NULL
gene	NULL
transcription	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9:373-398	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
S.	NULL
Sen	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
lymphoid-specific	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323	NULL
:	NULL
640-643	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bor	NULL
.	NULL

Tanaka	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Z.	NULL
Ben-Sasson	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
Paul	NULL
.	NULL

1991	NULL
.	NULL

IL-4	NULL
increases	NULL
IL-2	NULL
production	NULL
by	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
accessory	NULL
cell-independent	NULL
stimuli	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:3831-3839	NULL
.	NULL

Tendler	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
S.	NULL
J.	NULL
Greenberg	NULL
,	NULL
J.	NULL
D.	NULL
Burton	NULL
,	NULL
D.	NULL
Danielpour	NULL
,	NULL
S.-J	NULL
.	NULL

Kim	NULL
,	NULL
W.	NULL
A.	NULL
Blattner	NULL
,	NULL
A.	NULL
Manns	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Waldmann	NULL
.	NULL

1991	NULL
.	NULL

Cytokine	NULL
induction	NULL
in	NULL
HTLV-1	NULL
associated	NULL
myelopathy	NULL
and	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
:	NULL
alternate	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
retroviral	NULL
pathogenesis	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

46:302-311	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
M.	NULL
Flanagan	NULL
,	NULL
C.	NULL
A.	NULL
Edwards	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
early	NULL
gene	NULL
expression	NULL
in	NULL
T-lymphocytes	NULL
by	NULL
Oct-1	NULL
and	NULL
an	NULL
inducible	NULL
protein	NULL
,	NULL
OAP40	NULL
.	NULL

Science	NULL
254:558-562	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
J.	NULL
P.	NULL
Northrop	NULL
,	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:421-452	NULL
.	NULL

Wright	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
K.	NULL
C.	NULL
Gunter	NULL
,	NULL
H.	NULL
Mitsuya	NULL
,	NULL
S.	NULL
G.	NULL
Irving	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Expression	NULL
of	NULL
a	NULL
zinc	NULL
finger	NULL
gene	NULL
in	NULL
HTLV-I-	NULL
and	NULL
HTLV-II-transformed	NULL
cells	NULL
.	NULL

Science	NULL
248:588-591	NULL
.	NULL

